อ่านเพิ่มเติม
21:23 · 25 āļ•āļļāļĨāļēāļ„āļĄ 2022

Adidas shares tumble after terminated partnership with Kanye West 📉

Adidas
āļŦāļļāđ‰āļ™
ADS.DE, Adidas AG
-
-

Sports footwear and apparel manufacturer Adidas (ADS.DE) has announced that it has terminated its marketing agreement with rapper Kanye West. The reason for Adidas' withdrawal from the partnership is a series of 'anti-Semitic and racist' posts by the rapper, who has been blocked on Twitter. The company's shares have already lost nearly 70% since peaking in 2021:

  • Adidas has terminated its agreement with Ye, is phasing out its Yeezy product line and is halting all financing for the brand associated with Kanye West's image;
  • The company estimates a €250 million negative short-term impact on total annual net income as a result of the withdrawal.

Adidas will present its quarterly report on November 9.

​​​​​​​Adidas shares (ADS.DE), W1 interval. Compared to U.S. Nike (NKE.US), the sell-off in Adidas shares is much deeper. Investors are worried about the crisis in China, supply chain problems and an energy crisis that could undermine the company's margins. The company is also weighed down by the dire sentiment lingering on the German stock market. The severance of the Ye deal is another 'blow to the company. Looking at the fundamental side, however, the stock may look increasingly attractive to long-term investors relying on fundamental analysis. The termination of Ye's contract is likely to have only a short-term impact on the German giant's operations. Source: xStation5

31 āļ˜āļąāļ™āļ§āļēāļ„āļĄ 2025, 09:29

US OPEN: āļ§āļ­āļĨāļĨāđŒāļŠāļ•āļĢāļĩāļ—āļˆāļąāļšāļ•āļēāļĢāļēāļĒāļ‡āļēāļ™āļāļēāļĢāļ›āļĢāļ°āļŠāļļāļĄ FOMC

31 āļ˜āļąāļ™āļ§āļēāļ„āļĄ 2025, 09:25

DE40: DAX āđāļ•āļ°āļĢāļ°āļ”āļąāļšāļŠāļđāļ‡āļŠāļļāļ”āđƒāļ™āļĢāļ­āļš 2.5 āđ€āļ”āļ·āļ­āļ™ ðŸ“ˆ Rheinmetall āļžāļļāđˆāļ‡āļŦāļĨāļąāļ‡āļ„āļ§āļēāļĄāļ•āļķāļ‡āđ€āļ„āļĢāļĩāļĒāļ”āļĢāļ°āļŦāļ§āđˆāļēāļ‡āļĢāļąāļŠāđ€āļ‹āļĩāļĒ–āļĒāļđāđ€āļ„āļĢāļ™āļāļĨāļąāļšāļĄāļē

30 āļ˜āļąāļ™āļ§āļēāļ„āļĄ 2025, 08:14

US OPEN: āđ€āļ›āļīāļ”āļ•āļĨāļēāļ”āļ•āđ‰āļ™āļŠāļąāļ›āļ”āļēāļŦāđŒāļ”āđ‰āļ§āļĒāđāļĢāļ‡āļāļ”āļ”āļąāļ™āđ€āļĨāđ‡āļāļ™āđ‰āļ­āļĒ āļ—āđˆāļēāļĄāļāļĨāļēāļ‡āļ„āļ§āļēāļĄāļ•āļķāļ‡āđ€āļ„āļĢāļĩāļĒāļ”āļ—āļēāļ‡āļ āļđāļĄāļīāļĢāļąāļāļĻāļēāļŠāļ•āļĢāđŒ

24 āļ˜āļąāļ™āļ§āļēāļ„āļĄ 2025, 08:46

Novo Nordisk – āļˆāļēāļāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļŠāļđāđˆāđ‚āļ­āļāļēāļŠ

āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļ•āļĨāļēāļ”āļžāļĢāđ‰āļ­āļĄāļĨāļđāļāļ„āđ‰āļēāļ‚āļ­āļ‡ XTB Group āļāļ§āđˆāļē 2 000 000 āļĢāļēāļĒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ